The Centre for Molecular Pathology, a collaborative initiative between The Royal Marsden and The Institute of Cancer Research
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have successfully renewed their joint Biomedical Research Centre.
Together, the ICR and The Royal Marsden were awarded £43 million over five years by the National Institute for Health Research.
They were once again designated as a Biomedical Research Centre — the only BRC specifically focused on cancer.
The funding, which is paid to The Royal Marsden, begins in April 2017.
Underpinning cutting-edge research
The money will underpin our cutting-edge translational and clinical research so new findings can reach the clinic as soon as possible for the benefit of patients.
It will help support our new joint research strategy, which aims to combat cancer evolution and drug resistance - the single biggest challenge in cancer research and treatment.
The funding bid proposed to support a number of specific research areas including treatment of breast cancer, prostate cancer, gastrointestinal cancers, and other rare forms of cancer, and development of innovative forms of image-guided radiotherapy.
The bid covered themes such as improvements in the use of digital data, precision medicine and use of liquid biopsies.
The international peer review panel highlighted that the partnership was very strong in translational cancer research.
Supporting our joint research strategy
Professor Paul Workman, Chief Executive of the ICR, said: “I’m pleased that we have secured renewal of funding for the BRC in what is a highly competitive funding environment.
“The BRC will play a crucial role in providing infrastructure and other funding to support the delivery of the ICR’s and The Royal Marsden’s new joint research strategy to overcome the challenges posed by cancer’s complexity, adaptability and evolution through scientific and clinical excellence, innovation and partnership.”